Therapeutic Asset Ratings
394 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Benadryl
Pancreatic Ductal Adenocarcinoma
Merck Sharp & Dohme LLC
P1/2
CC
(41)
Gocatamig
Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
P1/2
CC
(41)
Levoleucovorin
Esophageal Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(41)
Lorazepam
Pancreatic Ductal Adenocarcinoma
Merck Sharp & Dohme LLC
P1/2
CC
(41)
Patritumab Deruxtecan
Esophageal Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(41)
Sacituzumab Tirumotecan
Esophageal Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(41)
Vibostolimab
Metastatic Prostate Carcinoma
Merck Sharp & Dohme LLC
P1/2
CC
(41)
mk-4464
Neoplasm
Merck Sharp & Dohme LLC
P1
CC
(40)
mk-5720
Schizophrenia
Merck Sharp & Dohme LLC
P1
CC
(40)
Ifinatamab Deruxtecan
Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(40)
Lorazepam
Colorectal Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(40)
mk-1088
Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(40)
mk-3120
Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(40)
Sacituzumab Tirumotecan
Colorectal Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(40)
mk-0472
Metastatic Malignant Neoplasm
Merck Sharp & Dohme LLC
P1
C
(39)
mk-1084
Metastatic Malignant Neoplasm
Merck Sharp & Dohme LLC
P1
C
(39)
mk-1484
Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC
P1
C
(39)
mk-6837
Metastatic Neoplasm
Merck Sharp & Dohme LLC
P1
C
(39)
mk-0472
Cancer
Merck Sharp & Dohme LLC
P1
C
(36)
Showing 376 to 394 of 394 assets
Previous
Page 16 of 16
Next
